<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Cancer pharmacology</title>
    <subTitle>an illustrated manual of anticancer drugs</subTitle>
  </titleInfo>
  <titleInfo type="alternative">
    <title>Cancer pharmacology</title>
  </titleInfo>
  <name type="personal">
    <namePart>Emadi, Ashkan</namePart>
    <role>
      <roleTerm type="text">editor.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Karp, Judith E.</namePart>
    <role>
      <roleTerm type="text">editor.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">bibliography</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">nyu</placeTerm>
    </place>
    <place>
      <placeTerm type="text">New York, NY</placeTerm>
    </place>
    <publisher>Springer Publishing Company</publisher>
    <dateIssued>c2024</dateIssued>
    <dateIssued encoding="marc">2024</dateIssued>
    <edition>Second edition.</edition>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
    <extent>xvi, 454 pages : color illustrations ; 26 cm</extent>
  </physicalDescription>
  <abstract>"We are living in an exciting time for cancer pharmacology. The fusion of multiple disciplines of basic and clinical science is creating effective, life-prolonging therapies for a growing number of malignancies. The progress is electrifying and the promise for patients is exhilarating!"--</abstract>
  <tableOfContents>Drug Development in Oncology / Edward A. Sausville and Ashkan Emadi -- Pharmacogenomics / Milly Graveno -- Critical Components of Clinical Trials Development : From Bench to Bedside and Back / S. Percy Ivy, Richard F. Little, and Joshua F. Zeidner -- Drug Development and Regulatory Considerations / Vicky Hsu, Matthew D. Thompson, Donna Przepiorka, and Olanrewaju O. Okusanya -- Alkylating Agents / Ashkan Emadi and Edward A. Sausville -- Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases / Ashkan Emadi and Judith E. Karp -- Antimetabolites : Antifolates / Justin Lawson -- Antimitotics / Edward A. Sausville and Ashkan Emadi -- DNA Repair, Apoptotic Pathways, and CDK Inhibitors / Mira A. Kohorst and Scott H. Kaufmann -- Epigenetic Modulators / Sergiu Pasca and Lukasz P. Gondek -- Differentiating Agents and Microenvironment / Yuya Nagai and Gabriel Ghiaur -- Targeted Therapeutics (Small Molecules) / Yuchen (Jake) Liu and Ashkan Emadi -- Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer / Amy M. Fulton and Katherine H. R. Tkaczu -- Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer / Vincent C. O. Njar and Arif Hussain -- Multiple Myeloma as a Paradigm for MultiTargeted Intervention / Kathryn Maples and Sagar Lonial -- Transplant-Related Agents : Focus on Graft vs. Host Disease Prevention and Treatment / Vedran Radojcic -- Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, and Cytokine-Directed Agents / Alison Duffy and Ciera Bernhardi -- Immunotherapeutics : Immune Checkpoint Inhibitors, Vaccines, Bispecifics, and Engineered T Cells / Mark Yarchoan and Elizabeth Jaffee.</tableOfContents>
  <note type="statement of responsibility">edited by Ashkan Emadi, Judith E. Karp.</note>
  <note>Includes bibliographical references and index.</note>
  <note>PHR</note>
  <subject authority="mesh">
    <topic>Antineoplastic Agents</topic>
    <topic>pharmacology</topic>
  </subject>
  <subject authority="mesh">
    <topic>Neoplasms</topic>
    <topic>drug therapy</topic>
  </subject>
  <subject authority="mesh">
    <topic>Molecular Targeted Therapy</topic>
  </subject>
  <subject authority="mesh">
    <topic>Pharmacy</topic>
  </subject>
  <classification authority="lcc">RC271.C5 C3224 2024</classification>
  <classification authority="ddc" edition="23">616.994061</classification>
  <classification authority="nlm">QV 269</classification>
  <relatedItem type="otherFormat" displayLabel="Online version:">
    <titleInfo>
      <title>Cancer pharmacology</title>
    </titleInfo>
    <originInfo>
      <publisher>New York, NY : Springer Publishing Company, [2024]</publisher>
      <edition>Second edition.</edition>
    </originInfo>
    <identifier type="local">(DLC) 2023005638</identifier>
  </relatedItem>
  <identifier type="isbn">9780826149329</identifier>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="lccn">2023005637</identifier>
  <recordInfo>
    <recordContentSource authority="marcorg">DNLM/DLC</recordContentSource>
    <recordCreationDate encoding="marc">251015</recordCreationDate>
    <recordChangeDate encoding="iso8601">20251015104101.0</recordChangeDate>
    <recordIdentifier source="BD-DhAAL">44938</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
